公开(公告)号：US20130039984A1

公开(公告)日：2013-02-14

申请号：US13653994

申请日：2012-10-17

Applicant: Novartis AG

Inventor： Daniel Kaufmann ,  Nicole Bieri ,  Ulrich Meier ,  Ranjit Thakur ,  Zdenek Zencak ,  Christa Hartmann ,  Andreas Meyer

IPC: A61K33/26 ,  A61K9/28 ,  A61P9/00

CPC classification number: B01J20/048 ,  A61K33/26 ,  A61M1/3486 ,  A61M1/3679 ,  B01J20/0229 ,  B01J20/06 ,  B01J20/24 ,  B01J2220/46 ,  B01J2220/4825 ,  B33Y80/00 ,  C01G49/06

Abstract: The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.

公开(公告)号：US11786498B2

公开(公告)日：2023-10-17

申请号：US15737985

申请日：2015-07-02

Applicant: Novartis AG

Inventor： David Hook ,  Bin Hu ,  Florian Karl Kleinbeck ,  Ulrich Meier ,  Sibylle Mueller ,  Jean-Paul Mutz ,  Jan Schlomach ,  Paul Allen Sutton ,  Liladhar Murlidhar Waykole ,  Bernhard Wietfeld

IPC: A61K31/22 ,  A61P9/10 ,  A61P9/06 ,  A61P25/02 ,  C07C229/34 ,  A61P9/12 ,  A61P25/06 ,  A61K31/4178 ,  A61K31/423

CPC classification number: A61K31/22 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P25/02 ,  A61P25/06 ,  C07C229/34 ,  A61K31/4178 ,  A61K31/423 ,  A61K2300/00 ,  C07B2200/13

Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.

公开(公告)号：US11291661B2

公开(公告)日：2022-04-05

申请号：US16815183

申请日：2020-03-11

Applicant: NOVARTIS AG

Inventor： Geoffrey Gogniat ,  Saran Kumar ,  Ulrich Meier ,  Mario Rentsch

IPC: A61K31/46 ,  A61P1/16 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50

Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.